Paymon Banafshe, DO
Adult Medicine · Los Angeles, CANPI 1346341575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 37.8% of the total.
Across 93 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$657
- Lilly USA, LLC$197
- Novo Nordisk$184
- Amgen$144
- Gilead$112
- Abbott$94
- plus $349 from 7 others
What the payments were for
- Food & beverage$1,71999%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $657 |
| Lilly USA, LLC | 9 | $197 |
| Novo Nordisk | 9 | $184 |
| Amgen | 13 | $144 |
| Gilead | 4 | $112 |
| Abbott | 4 | $94 |
| Sanofi-aventis U.S. LLC | 4 | $74 |
| Pfizer | 3 | $73 |
| Johnson & Johnson | 3 | $66 |
| Exact Sciences | 2 | $46 |
| Alk-abello, Inc | 2 | $42 |
| Bayer | 1 | $25 |
| Boehringer Ingelheim | 1 | $22 |
How this compares
$1,737 in reported general payments places this provider in the 80th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $122,154 |
| JardianceEmpagliflozin | 52 | $51,342 |
| JanuviaSitagliptin Phosphate | 46 | $36,694 |
| EliquisApixaban | 80 | $36,068 |
| SantylCollagenase Clostridium Hist. | 50 | $29,314 |
| FarxigaDapagliflozin Propanediol | 20 | $25,006 |
| MyrbetriqMirabegron | 35 | $11,430 |
| XareltoRivaroxaban | 27 | $11,383 |
| TradjentaLinagliptin | 11 | $10,272 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $8,852 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,568 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,455 |
| EntrestoSacubitril/Valsartan | 20 | $7,334 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,198 |
| Sevelamer Carbonate | 16 | $4,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $184 | $122,154106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $22 | $61,61363 claims |
| PfizerEliquis | $73 | $36,06880 claims |
| AstraZenecaFarxiga | $657 | $25,00620 claims |
| Johnson & JohnsonXarelto | $66 | $11,38327 claims |
| Lilly USA, LLCHumalog | $197 | $1,28624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 221 adult medicine providers in California.
Other adult medicine in Los Angeles
- Natalia GuzmanLos Angeles$583K
- Tin WongLos Angeles$18K
- Reza MesbahLos Angeles$8K
- Robert TracyLos Angeles$2K
- Susan HutchinsonLaguna Hills$1M
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
- Patrick WelchArroyo Grande$20K
- Craig BobsonManteca$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.